The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Lacosamide Fresenius Kabi 10 mg/ml solution for infusion

Fresenius Kabi Deutschland GmbHPA2059/078/001

Main Information

Trade NameLacosamide Fresenius Kabi 10 mg/ml solution for infusion
Active SubstancesLacosamide
Dosage FormSolution for infusion
Licence HolderFresenius Kabi Deutschland GmbH
Licence NumberPA2059/078/001

Group Information

ATC CodeN03AX18 lacosamide


License statusAuthorised
Licence Issued03/06/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back